600 prescriptions have now been written for MGC Pharma medicinal cannabis products
Health & Biotech
Health & Biotech
Special Report: Seed-to-pharmacy bio-pharma company MGC Pharma has hit a new milestone, with 600 prescriptions now having been written for its products.
MGC Pharma (ASX:MXC), which currently has two medicinal cannabis products available — CannEpil for epilepsy and MXP100 for mild neurological disorders, inflammatory and for hepatoma patients — told the market today the number of prescriptions for its standardised, affordable cannabinoid medicines had passed 600.
The products are being prescribed in Australia and the UK, where the company has distribution deals with innovative local businesses. More than 200 of these have come in the first few weeks of October, following the 200 and 400-prescription milestones that came in quick succession.
Roby Zomer, the company’s co-founder and managing director said the fast-paced uptake was proof positive of the quality and cost competitiveness of his company’s medicines, which are being prescribed to patients in need by specially-licensed doctors.
“The increased momentum of new prescriptions in Australia and the UK is a testament to the effectiveness of our phytocannabinoid medicines and growing recognition from, and use by, the medical community,” he said.
“I believe that this is just the beginning of our market penetration and we will be able to sustain this attractive growth trajectory. With our unique EU-GMP production and key market distribution infrastructure now established, we can meet this increasing demand for our offering of phytocannabinoid derived medicines in our existing and future markets in both Europe and Australasia.”
Further to this, a number of other patients are being treated with MGC Pharma products globally via participation in ongoing clinical research.
The company has distribution deals Grow Biotech and IPS Specials across more than 5,500 UK pharmacies and Health House and Cannvalate in Australia.